Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Aprea Therapeutics Inc

APRE ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: STRONG BUY

Last Close

$0.66

▼ -1.28%

Market Cap $8.56M · Vol 1.58K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$8.56M

Micro Cap

Div Yield

N/A

EPS Growth

+73.19%

YoY

RSI (14)

61.88

Momentum

Beta

1.59

vs Market

52W High

$1.72

61.49% below

52W Low

$0.55

20.88% above

Volume

1.58K

Avg 6.83K

P/B

0.56

Price-to-book

ROE

N/A

Return on equity

Free Float

79.50%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Aprea Therapeutics Inc (APRE) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does APRE pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+1.86%

-9.06%

-29.61%

+8.70%

YTD

-22.34%

-60.80%

-81.60%

-99.09%

Financials & Valuation

TTM · Annual

Total Revenue	$285.76K
Net Income	$-12,599,570.00
Revenue Growth (YoY)	-100.00%
Gross Margin	100.00%
Operating Margin	-4,631.12%
Net Profit Margin	-4,409.16%
ROE	N/A
ROA · ROIC	-63.14% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	19.52
P/B	0.56
P/FCF	N/A
EPS Growth	+73.19%
Outstanding Shares	12.59M

Technical Indicators

50-Day SMA	$0.71
200-Day SMA	$0.86
RSI (14)	61.88
Beta	1.59
52-Week High	$1.72
52-Week Low	$0.55

Volume Today	1.58K
Avg Daily Volume (30D)	6.83K
Relative Volume	0.23x
Volatility (10D)	36.76
Volatility (30D)	39.73
Free Float	79.50%

Analyst Consensus

STRONG BUY

Current Price $0.66

Mean Target $3.55

52W Low$0.55 52W High$1.72

Current

Target

$0.55 $1.72

Current Analyst target

+435.93% upside potential · 4 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00Q6Q3KV6

ISINUS03836J2015

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 9, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. It is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. It also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target.